92 results about "Acute ischemic stroke" patented technology

APRIL research shows that in a selected stroke patient, infusion of 0.2 mg / kg of ApTOLL (SEQ ID NO: 1) in combination with intravascular treatment is safe, and the death rate of 90 days is reduced. ApTOLL has proved to limit intracranial hemorrhage and reperfusion injury which may occur after recanalization, and also improve early nerve injury and long-term disability. ApTOLL molecules are provided for reducing the risk of intracranial or secondary bleeding after acute ischemic stroke, reducing nerve injury, and improving nerve recovery in a subject.

The embodiment of the invention provides a cerebral apoplexy focus detection and scoring method and device based on a multi-modal medical image. The method comprises the following steps: acquiring medical images of various different modals of a suspected acute ischemic cerebral apoplexy patient; performing registration fusion and focus labeling on the medical images of different modalities based on an attention mechanism to obtain a labeled first modal image; training a target detection model of a YOLOv8 framework based on Swin-Transform improvement by using the labeled first modal image, and carrying out target detection on the to-be-detected image based on the trained target detection model to obtain an infarction region detection result; training a semantic segmentation model by using the labeled ASPECT scoring and partitioning brain atlas, performing scoring region segmentation on the to-be-detected image based on the trained semantic segmentation model, and outputting the ASPECT scoring and partitioning brain atlas; and mapping the infarct area detection result to the ASPECT score partition brain map, and calculating to obtain an ASPECT score.

The invention discloses a pharmaceutical composition which comprises anisodine or salt thereof and 2-borneol or related substances thereof. The pharmaceutical composition provided by the invention has a synergistic effect in treatment of cardia-cerebrovascular diseases, especially central nervous diseases such as acute ischemic stroke, can effectively improve the effect of patients with cerebrovascular diseases, especially central diseases such as acute ischemic stroke, and improves the quality of life.

The invention discloses an early recognition and early warning system for acute ischemic stroke symptoms, and relates to the technical field of health detection. Comprising an image acquisition module, a voice acquisition module, a data processing module, a display module and an alarm module, the voice acquisition module is used for acquiring user audio signals; the data processing module is used for processing the collected signals to generate corresponding face judgment signals, limb judgment signals and audio judgment signals; the display module is used for displaying sentences needing to be read by the user; and the alarm module is used for judging whether the user has an acute ischemic stroke early symptom or not according to the face judgment signal, the limb judgment signal and the audio judgment signal, and if so, dialing 120 and a contact person through the mobile phone. The method can significantly improve the early warning and prevention efficiency of cerebral apoplexy, is expected to play a greater role in the field of cerebral apoplexy prevention and treatment, and improves the prognosis and life quality of patients.

The invention relates to a stroke prognosis prediction model training method based on quantum computing and artificial intelligence, and relates to the technical field of prognosis effect prediction. According to the method, leukocyte community parameters are introduced into an acute ischemic stroke prognosis model for the first time, morphological function characteristics of leukocytes are detected through a flow cytometry, and compared with traditional inflammation indexes, the leukocyte prognosis model has higher sensitivity and objectivity and becomes an important index for predicting neurological function impairment; the indexes closely related to cerebral apoplexy prognosis are screened out through quantum calculation for the first time, and a new thought is provided for high-dimensional data feature screening; meanwhile, by comparing 14 traditional machine learning, integrated learning and deep learning models, it is judged that the LightGBM model is an acute ischemic stroke prognosis prediction model, and compared with the prior art, the LightGBM model is remarkably improved.

The invention provides a production process of an acute ischemic stroke neuroprotective agent, and particularly relates to a method for preparing an edaravone dextroborneol concentrated solution for injection, and the method comprises the following steps: adding a liquid medicine containing propylene glycol, edaravone, dextroborneol and sodium pyrosulfite into a liquid preparation tank; the temperature of the liquid medicine is controlled to be 0-50 DEG C, the pH value of the liquid medicine is adjusted to be 3.0-7.0, the liquid medicine is conveyed into an ampoule bottle through a conveying pipeline, the conveying pipeline is a pipe, and the ampoule bottle is filled with the liquid medicine through the pipe through a pump. According to the preparation method, the loss of effective components in the production and storage process of the liquid medicine is greatly reduced, the stability of the liquid medicine can be remarkably improved, and the preparation process is good in consistency, repeatable and suitable for industrial production.

The invention relates to the technical field of intelligent disease prediction, in particular to a cerebral apoplexy postoperative vascular recanalization effect prediction method and system based on multiple modalities, and the method comprises the steps: obtaining clinical information and NCCT images of a patient; preprocessing the clinical information to obtain clinical modal features; preprocessing the NCCT image to obtain a denoised NCCT image; inputting the denoised NCCT image into a deep convolutional neural network to obtain modal features of the NCCT image; performing comparative learning according to the clinical modal features and the NCCT image modal features, and constructing a comparative loss function to obtain comparative learning loss; fusing the NCCT image modal features and the clinical modal features to obtain fused modal features, and calculating the loss of the fused modal features; and calculating dynamic total loss, and outputting a prediction result of vascular recanalization after thrombus extraction of the acute ischemic stroke patient. According to the method, accurate prediction of the effectiveness of postoperative vascular recanalization is realized through mechanisms such as deep neural network feature extraction, multi-head cross attention and comparative learning.

The invention discloses a bionic nano system for treating acute ischemic stroke and application of the bionic nano system. According to the preparation method disclosed by the invention, the TNK-DNaseI (at) ZIF-8 nano-particles are prepared by loading the ZIF-8 with the TNK-DNaseI (at) ZIF-8 and then the TNK-DNaseI (at) ZIF-8 nano-particles are coated with the natural platelet membrane, so that the TNK-DNaseI (at) ZPM bionic nano-system is prepared. The bionic nano system can achieve efficient thrombolysis, obviously reduce the infarct area, improve neurological impairment and reduce bleeding complications. The invention provides a new drug choice for treating the acute ischemic stroke, and has a wide application prospect in the aspects of clinically treating the acute ischemic stroke and improving the prognosis of a patient with the acute ischemic stroke.

The invention relates to 4 serum peptide patterns for diagnostics of intracranial hemorrhagic stroke (ICH) in humans and differential diagnosis from acute ischemic stroke that are defined using a list of the 34 quantitative peptides that in sera of patients with ICH are increased 2 folds or more as compared with individuals without stroke and patients with acute ischemic stroke and a list of 16 qualitative peptides detectable in sera of the patients with ICH but not detectable in the sera of individuals without stroke and in sera of patients with acute ischemic stroke.

The invention relates to the field of physiology and molecular biology, and discloses an IGF2BP1 targeting reagent and application of IGF2BP1 protein in treatment of acute ischemic stroke.

The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.

In MRI examinations of patients with acute ischemic stroke, it is often difficult for patients to fix and hold their heads due to impaired consciousness or limb weakness. Therefore, this invention provides a tool that is structurally rational, easy to operate, and effectively enhances the head fixation effect. [Solution] A tool to support MRI examination, comprising a base 1, a head rest member 2 with adjustable anterior-posterior position, a lateral limiting member 3 with an elastic buffer layer, and an adjustment mechanism 4. The head rest member slides relative to the base to adapt to the length of the patient's neck. The lateral limiting member is biased inward by a compression coil spring and flexibly holds both sides of the head with an elastic buffer layer, absorbing and suppressing involuntary movements. The adjustment mechanism uses a single reverse-threaded adjustment rod to synchronously and symmetrically move the left and right limiting plates, enabling precise adjustment according to the head circumference. This effectively limits multi-directional micro-movements of the head during imaging and improves image stability.

The present invention relates to a traditional Chinese medicine composition for treating stroke. The traditional Chinese medicine composition is prepared from 10 - 30 parts by weight of Poria cocos, 5 - 25 parts by weight of Uncaria rhynchophylla, 5 - 25 parts by weight of Salvia miltiorrhiza, 3 - 18 parts by weight of Citrus reticulata Blanco, 3 - 18 parts by weight of Gastrodia elata Blume, 3 - 18 parts by weight of Ligusticum chuanxiong Hort., 3 - 18 parts by weight of Pinellia ternata (Thunb.) Breit., 1 - 15 parts by weight of Arisaema cum Bile, and 1 - 15 parts by weight of Carthamus tinctorius L. The traditional Chinese medicine composition of the present invention resolves phlegm and extinguishes wind, promotes blood circulation and dredges collaterals, has high safety, and has remarkable curative effects on treating stroke, especially acute ischemic stroke.

An arterial access device has an internal lumen and a proximal port, the arterial access device sized and shaped to be inserted directly into an arterial access site in the common carotid artery such that the lumen provides a passageway for an interventional device to be inserted via the proximal port into the carotid artery. The arterial access device has a distal portion that is configured to be inserted into an arterial pathway through the access site, and a proximal portion configured to extend outward from the access site when the distal portion is in the arterial pathway.

The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg / kg / dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

Disclosed is a non-invasive system and related methods to deliver electrical current to ischemic brain tissue rapidly with minimal set up, to treat acute ischemic stroke via direct cytoprotection and by collateral blood flow enhancement promoting recanalization of occluded vessel. In one embodiment, the system includes a cap with plurality of electrodes which are operable in combination to deliver an electrical current when in contact onto skin of the head region of the subject. In one embodiment, the electrical current delivery is individualized to target each individual's ischemic tissue only. In one embodiment, the electrode positioning can be selected from pre-determined electrode montages according to the location of the ischemia and vessel occlusion site. In one embodiment, the system can be applied as a standalone treatment or adjunct to reperfusion therapies to salvage the at-risk ischemic tissue (aka penumbra) and improve patient outcomes.

In an automated detection system for acute ischemic stroke, a preprocessor performs registration on a whole-brain image and a standard-brain spatial template to extract individual brain region masks from the whole-brain image. A deep learning encoder performs feature extraction on the whole-brain image and the individual brain region masks, thereby converting the whole-brain image into 2D whole-brain slice images. A first processor maps the individual brain masks onto the whole-brain slice images for registration, thereby generating sets of brain region slice images. A second processor computes the stroke-related weight values of the slice images of each of the sets of brain region slice images and sums the weight values to obtain the characteristic value of each brain region. A disparity-aware classifier determines whether any brain region has acute ischemic stroke according to the characteristic value of each brain region.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

Disclosed in the present invention is a pharmaceutical composition, comprising anisodine or a salt thereof and 2-borneol or a related substance thereof. The pharmaceutical composition provided in the present invention exhibits synergistic effects in the treatment of cardiovascular and cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, and can effectively improve outcomes of patients with cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, thereby enhancing the quality of life of the patients.

The application belongs to the field of Zhuang and Yao medicine treatment of acute ischemic stroke, and discloses a Zhuang and Yao medicine compound medicine, a preparation method and application thereof in treating acute ischemic stroke. The Zhuang and Yao medicine compound medicine comprises the following raw materials in parts by weight: Ficus tikoua 55-62 parts, Camptotheca acuminata 12-17 parts, Ilex hainanensis 26-35 parts and Saposhnikovia divaricata 13-18 parts. The four raw materials are put into clean water, and the raw materials are prepared into a medicinal liquid to obtain the Zhuang and Yao medicine compound medicine. The Zhuang and Yao medicine compound medicine is cheap, convenient to use, has remarkable curative effect, can dredge the dragon road and the toxic evil and toxic side effects of the fire road, and has a simple preparation process.

A system of devices for treating an artery includes an arterial access sheath adapted to introduce an interventional catheter into an artery and an elongated dilator positionable within the internal lumen of the sheath body. The system also includes a catheter formed of an elongated catheter body sized and shaped to be introduced via a carotid artery access site into a common carotid artery through the internal lumen of the arterial access sheath. The catheter has an overall length and a distal most section length such that the distal most section can be positioned in an intracranial artery and at least a portion of the proximal most section is positioned in the common carotid artery during use.

An arterial access device has an internal lumen and a proximal port, the arterial access device sized and shaped to be inserted directly into an arterial access site in the common carotid artery such that the lumen provides a passageway for an interventional device to be inserted via the proximal port into the carotid artery. The arterial access device has a distal portion that is configured to be inserted into an arterial pathway through the access site, and a proximal portion configured to extend outward from the access site when the distal portion is in the arterial pathway.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

The present invention discloses the use of a compound in the preparation of a medicament for treating and / or preventing stroke. The compound is 2,3-dihydronaphtho[1,2-b]furan-4,5-dione, and the stroke includes acute ischemic stroke or ischemic reperfusion brain injury. The compound can effectively treat or prevent acute ischemic stroke by alleviating the acute brain injury caused by acute ischemic stroke or ischemic reperfusion, reducing the volume of cerebral infarction after acute ischemic stroke, alleviating cerebral edema after stroke, and improving neurological function after stroke.